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COMMUNICATION FROM THE COMMISSION TO THE COUNCIL AND THE 
EUROPEAN PARLIAMENT 
A European Programme for Action to Confront HIV/AIDS, Malaria and Tuberculosis 
through External Action (2007-2011) 
1. THE POLICY CONTEXT AND SCOPE OF THE PROGRAMME FOR ACTION 
In October 2004, the European Commission (EC) adopted a Communication entitled 
“A Coherent European Policy Framework for External Action to Confront 
HIV/AIDS, Malaria and Tuberculosis (TB)” – COM(2004) 726 final1 This was 
prepared based on a second progress report on the “EC Programme for Action: 
Accelerated action on HIV/AIDS, malaria and tuberculosis in the context of poverty 
reduction” that highlighted key results and areas where the EC needs to reinforce or 
take further action.2 
The Council welcomed the policy framework, urged the EC and the EU Member 
States (EU MSs) to enhance their cooperation and coordination to confront the three 
diseases and requested the Commission to present a Programme for Action (PfA).3 
This PfA responds to the Council Conclusions on harmonisation,4 by proposing 
collective EU (EC and EU MSs) action to support country-lead programmes to 
confront the three diseases5 and action at global level in selected areas where the EU 
can add value. 
The PfA will cover developing and middle-income countries. It is based on the 
general principle of benefiting from best practices and experience in the external 
actions and from the relevant Community policies. Later this year, the Commission 
will adopt a Communication on how to confront HIV/AIDS within the EU and in the 
neighbouring countries. Country strategy programmes (CSPs) and European 
Neighbourhood Policy Action Plans will define an appropriate strategy and set of 
actions.  
The response to HIV/AIDS, malaria and TB is still underfunded. Additional 
funds will mainly have to come from external sources – public and private. The 
projected annual external resource gap will continue to grow and is estimated to 
reach US$14.9 billion by 2007 – US$11.5 billion for HIV/AIDS, US$2.6 billion for 
malaria, and US$0.8 billion for TB.6 These figures only partly include resources for 
strengthening of the health system in partner countries, which is a prerequisite for 
                                                 
1 COM(2004) 726 final 
2 SEC(2004) 1326 
3 Council Conclusions of 23 November 2004 (doc. 15158/04) 
4 Council Conclusions of 24 November 2004 (doc. 15159/04) 
5 References to common action in countries are made under action points 1, 3, 5, 6, 9, 10, 13, 15, 16 and 
18 and to common action at global level under action points 19, 23, 26, 27, 28, 29 and 30. 
6 The Global Fund, Addressing HIV/AIDS, Malaria and Tuberculosis: The Resource Needs of the Global 
Fund 2005-2007, 2005 
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progress, and the need for further investment in the research and development of new 
tools and interventions. 
A major objective of this PfA is to increase efforts to scale up interventions that 
have shown results. The EU should aim for a contribution that helps to fill the 
financing gap for the three diseases and meet the Millennium Development Goal 
(MDG) 6 and that reflects Europe’s weight and importance as an international 
partner in development. 
2. EU ACTIONS AT COUNTRY LEVEL 
Country leadership is the key to confront these diseases and their consequences 
through broad-based strategies. The participation of civil society – including people 
affected by the diseases – and partnership with public and private stakeholders, 
donors and international agencies are essential for scaling up efforts that lead to 
success. (See Annex 1.) 
2.1. Political and policy dialogue to support country-led strategies to confront the 
three diseases 
(1) The EU will reinforce its political dialogue with countries on key issues 
relating to leadership and governance. The dialogue will address the need for 
a comprehensive strategy with an appropriate balance between prevention, 
treatment and care, depending on the situation in each country. Other subjects 
for dialogue include children’s rights, women’s rights, and sexual and 
reproductive health and rights. The dialogue should also address the needs of 
orphans and vulnerable children. The “Framework” adopted in July 2004 
should be used by EC staff for this purpose.7 The dialogue should address 
other vulnerable groups, such as injecting drug users, prisoners, elderly 
people, people with disabilities, refugees and internally displaced 
populations, as well as issues around stigma and discrimination. The 
application of the Greater Involvement of People Living with AIDS (GIPA) 
principle needs to be extended to the three diseases.8 
(2) To help implement policy, the EC will prepare a toolkit for Delegations and 
services which will include guidelines for policy dialogue, programming 
guidelines offering advice concerning indicators and monitoring of country 
efforts, and reference documents. It will be reviewed and updated 
periodically. Awareness raising and training will be provided for EC staff. 
(3) The EU will share expertise to ensure that the EU collectively has a critical 
mass of expertise to play a constructive role in the policy and technical 
dialogue, including in PRSP reviews, sector policy dialogue and in the 
Country Coordinating Mechanisms (CCMs) of the Global Fund. In countries 
where the EC does not have specific expertise, Delegations will work actively 
with EU MS experts and other partners, including UN agencies. Such 
                                                 
7 The Framework for the Protection, Care and Support of Orphans and Vulnerable Children Living in a 
World with HIV and AIDS, July 2004 
8 For further information on the GIPA principle, see UNAIDS, 2004 Report on the Global AIDS Epidemic 
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arrangements may include shared programming, monitoring and reporting, 
and will make optimum use of EU regional expertise. 
(4) EC Delegations will promote health and disease prevention amongst staff, 
particularly for HIV/AIDS, building on the ILO Code of Practice on 
HIV/AIDS, while also addressing relevant issues concerning TB and malaria. 
In staff training, Delegations will be encouraged to use the training manual 
developed by ILO.9 Delegations will assist and support staff and their 
families through adequate social protection schemes. 
2.2. Capacity building to confront the three diseases 
(5) The EU will map TA resources available to countries with a view to 
developing a plan for shared TA, governed by a code of conduct for 
collective action. Such assistance should be provided, e.g. by UN agencies, at 
the request of broad-based national or regional bodies such as the CCMs and 
sector coordination platforms. 
(6) The EU will support the case for health being treated as an exceptional case 
in public sector reform programmes, increasing public spending to allocate a 
sufficient share of public expenditure to health (e.g. the 15% Abuja 
commitment for African countries), and will maintain its dialogue with the 
Bretton Woods institutions on the appropriate fiscal space for action on the 
three diseases. 
(7) The EC will strengthen national programmes to build clinical research 
capacity through the European and Developing Countries Clinical Trials 
Partnership (EDCTP). General support for life science research will be 
provided through the 7th Framework Programme for Research and 
Technological Development (FP7). The EC will also support synergy in the 
approach to health research (EDCTP) and health care activities at country 
level, in a selected number of partner countries. Synergies between capacity 
building for research and training of staff for health care should be fully 
explored. The EDCTP should play an integrating role by contributing to 
national and regional human resource plans for clinical research. Further 
efforts are needed to support complementary health care activities, including 
improving local or regional health services at clinical trials sites, 
reinforcement of human resources, building of new infrastructures such as 
hospital wards, and ensuring access to medical care coverage for the 
population during clinical trials. 
(8) The EC will provide further technical support to improve countries’ 
capacities to develop pharmaceutical policy, including through its strategic 
partnership with WHO. The EC will encourage WHO to identify key issues 
that pharmaceutical policy needs to address. 
(9) The EU will support countries in developing sound and efficient 
procurement policies and practices for pharmaceutical products and 
                                                 
9 http://www.ilo.org/public/english/protection/trav/aids/code/codemain.htm 
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commodities, such as condoms, long-lasting insecticide-treated bed nets (LL-
ITNs) and anti-retrovirals. 
(10) The EU will strive to exploit mutual synergies between programmes and 
measures to implement the Convention on the Rights of the Child, the Beijing 
agenda on gender equality, the Cairo agenda on sexual and reproductive 
health and rights (SRHR), and UNGASS and other UN strategies and 
programmes to confront HIV/AIDS, malaria and TB. 
(11) In countries where the EC supports the education sector, the EC will pursue 
through sector and policy dialogue the inclusion of lifeskill education and 
safe schools for children, especially girls, to increase protection against rape, 
pregnancy or infection with HIV/AIDS and other sexually transmitted 
diseases (STDs). The EC will help to establish and support codes of conduct, 
training of school staff, and community protection mechanisms. 
(12) In emergency situations and protracted crises, the EC Humanitarian Office 
(ECHO) will help to reduce the transmission of the three diseases, and the 
human distress and mortality they cause by mainstreaming basic HIV/AIDS 
preventive and palliative measures, both in its humanitarian programmes and 
via its implementing partners. This will include awareness-raising, 
information, training and the provision of prevention tools for humanitarian 
workers. Preventive and curative measures against malaria and TB already 
form an integral part of the humanitarian response supported by ECHO. 
Consultations on the three diseases with other donors and EC departments 
will become an essential part of the Linking Relief, Rehabilitation and 
Development (LRRD) process. 
(13) To help national initiatives to counter rape, violence against women, child-
trafficking and the spread of the three diseases in conflict-resolution, 
peacekeeping, and post-conflict situations, the EU will ensure that guidelines 
are developed and awareness-raising, information, training and 
prevention tools are provided for participants in such operations, in line 
with the UN Security Council Resolution of July 2000. 
(14) The EC will analyse the impact of HIV/AIDS, malaria and TB on human 
security, e.g. in terms of access to basic services and stability at state-level, 
including the impact of these diseases on governance and institutional 
performance. The results will feed into a response strategy to support 
countries affected. 
(15) The EU will support countries in collecting and monitoring sex- and age-
disaggregated data on HIV/AIDS, malaria and TB. The EC will promote 
the use of indicators that can be meaningfully monitored on an annual basis 
through national health information systems, including through behavioural 
surveillance surveys. In line with the “3 Ones”, as extended to malaria and 
TB, and ongoing efforts at donor harmonisation around country-led 
strategies, the EU will work with countries, WHO (building further on the 
Second Generation Surveillance Project, the Health Metrics Network, and the 
Roll-Back Malaria (RBM) and StopTB partnerships), UNAIDS and the 
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Global Fund towards joint monitoring and performance assessment based on 
common indicators and shared reporting. 
2.3. Financial resources to confront the three diseases 
(16) The EU will continue to provide resources to countries for confronting 
HIV/AIDS, malaria and TB, to be identified through appropriate 
mechanisms. 
(17) The EC will use partnerships and specific support to help finance highly cost-
effective interventions likely to yield rapid results, including: 
– Targeted distribution of free LL-ITNs and complementing social 
marketing strategies which encourage local production capacity 
– Targeted distribution of free contraceptives linked to increased 
investment in health promotion, and building capacity for social 
marketing 
– Provision of universal free access to voluntary counselling and testing 
(VCT) and antiretroviral drugs for HIV positive pregnant women. 
To achieve maximum impact, these should be delivered as part of a comprehensive 
package of interventions. 
(18) The EU will work with countries to address concerns identified in the High 
Level Forum on Health MDGs and the review of the MDG focus of PRSPs. 
Despite strong MDG commitments, there has not yet been a significant shift 
in resources to actions capable of accelerating progress towards the health 
MDGs. The EC will support further work and action linking national policy 
commitments to the MDGs more closely with financing decisions to 
reward investment in evidence-based strategies for accelerating progress 
towards the MDGs, in particular MDG 6. 
3. EU ACTIONS AT GLOBAL LEVEL 
The EC will also undertake action at regional and global level to confront the three 
diseases, in partnership with EU MSs and other key players. Selected areas for action 
include affordable pharmaceutical products, regulatory capacity, human 
resources in the health sector, and research and development of new tools and 
interventions. Global efforts to promote prevention, treatment and care remain a 
cornerstone for confronting the three diseases. 
(19) The EC will further develop its regional capacity through the use of regional 
health advisors, with specific focus on the three diseases. Tasks will include 
setting up a network of EU and partner expertise to exchange experience, 
share best practice, and promote regional cooperation in the fields of 
regulatory and procurement capacity. 
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3.1. Affordable and safe pharmaceutical products 
(20) The EC will monitor the implementation and the results of the EC 
Regulation to avoid trade diversion into the EU of certain key 
medicines.10 Through its dialogue with industry, the EC will encourage more 
companies to register a wide selection of their products under the rules 
established through the Regulation. 
(21) The EC will promote price transparency on pharmaceutical products and 
commodities used to confront the three diseases by asking countries to 
publish prices on products purchased by country programmes funded by the 
EC and by the Global Fund. Prices will be made available on the EC web site 
facilitating price comparisons, as a way of monitoring the impact of untying 
of aid. 
(22) The EC will uphold the principles reflected in the 2001 Doha Declaration on 
TRIPs and public health and in the August 2003 Decision by the WTO 
General Council. The EC has proposed the legislation needed by European 
companies to issue a compulsory licence in response to the procedure 
described in the Decision.11 The EC will monitor the implementation of the 
August decision by exporting and importing parties, identify bottlenecks and 
provide assistance to solve them. The EC will actively participate in 
negotiations with the aim of incorporating the Decision into the TRIPs 
Agreement through a formal amendment. 
3.2. Regulatory capacity and prequalification 
(23) The EC will cooperate with WHO, the European Medicines Agency (EMEA) 
and interested national regulatory bodies of EU MSs in support of the 
development of the capacity of national and regional bodies to perform 
scientific and regulatory tasks with respect to the evaluation and 
marketing authorisation of pharmaceutical products. This will include, in 
particular, scientific assistance in the framework of the so-called ‘Article 
58’,12 plus specific guidelines on key products. 
(24) The EC will help to establish regional cooperation networks of regulatory 
consultants and regional schemes of mutual recognition for marketing 
authorisation. EC support will include a feasibility study, in cooperation 
with the African Union (AU) on the setting-up of an African mutual 
recognition scheme for marketing authorisation. Cooperation should also help 
to establish regional centres of regulatory expertise in countries with 
potential in this field e.g. Brazil, South Africa and Thailand. The EC is ready 
to join forces with WHO to help set up an international advisory committee 
                                                 
10 Regulation (EC) 953/2003. OJ L 135, 3.6.2003, p.5 
11 Proposal for a Regulation of the European Parliament and of the Council on compulsory licensing of 
patents relating to the manufacture of pharmaceutical products for exports to countries with public 
health problems. COM(2004) 737 
12 Article 58 enables the EMEA to give a scientific opinion, in the context of cooperation with WHO, for 
the evaluation of certain medicinal products for human use intended exclusively for markets outside the 
Community. Regulation (EC) No 726/2004 (31 March 2004), Article 58, OJ L 136, 30.4.2004, p. 1 
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of impartial experts to provide technical, scientific and policy support for 
partner country regulatory agencies. 
(25) The EC will support the WHO prequalification project in its efforts to 
expand the geographical coverage and range of products. In addition to 
funding, EC support will include the sharing of expertise and human 
resources, and targeted support for local production initiatives in developing 
countries to upgrade Good Manufacturing Practices and submit proposals 
(bioequivalence and stability studies). 
3.3. Addressing the human resource crisis for health providers 
(26) The lack of trained health providers undermines efforts to scale up the 
provision of prevention, treatment and care services. The EU will support a 
set of innovative responses to the human resource crisis. At regional level, 
the EC will use its support for the AU and the New Partnership for Africa’s 
Development (NEPAD) to help ensure strong African leadership in the 
formulation and coordination of a response to the human resource crisis. The 
aim should be to increase incentives for health workers to remain in or return 
to developing countries or regions where the need is greatest rather than to 
create barriers to migration. Actions will include strengthening AU and 
NEPAD capacity to map the scale of the problem and facilitate regional 
dialogue on country, regional and global action needed to increase training 
and to retain and sustain increased human resource capacity. Improved 
opportunities for research may also help to prevent brain drain. Engaging the 
local communities in research activities, which could contribute to improving 
the overall level of health care, will also be encouraged. Strengthened synergy 
between EC supported research and health resources at local and regional 
level can further help improving health care. 
(27) By 2006, the EC will present a policy document on human resources 
within the broader health context, which will help to formulate specific 
measures and thus also have an impact on the implementation of this PfA. 
This strategy will include a discussion of the following topics: 
– a European Code for ethical recruitment practice, drawing upon and 
learning from experience in EU MSs with voluntary codes; 
– compensation for partner countries (e.g. through taxation by the EU 
MSs on recruitment) to make up for the recruitment of trained nationals 
from countries with a human resource crisis; 
– supporting the development of national plans for human resources 
through policy dialogue on sectors, CSPs and PRSPs; and 
– a Declaration of Global Solidarity, issued by the Council and the EU 
MSs, stating the key principles and objectives for supporting action on 
human resources in the health crisis. 
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3.4. New tools and interventions 
(28) The EC will support the research and development of new tools and 
interventions through projects designed to accelerate the development of 
new vaccines, drugs, microbicides and diagnostic tools for resource-poor 
settings. The EC will encourage the participation of research organisations 
and institutions from disease-endemic countries in collaborative research 
projects with European partners. The EC will provide support for the 
EDCTP while urging European countries, private charities and industry to 
provide significant funding and expertise for this initiative. In its dialogue 
with participating countries and companies, the EC will advocate the 
inclusion of clauses on affordability, intellectual property rights (IPR), 
manufacturing and regulatory approval. The EC will provide support for 
social-behavioural research, epidemiology and operational, health-
systems and applied research, and cost projection studies – including 
community capacity and preparedness to participate in clinical trials and to 
introduce new tools and interventions rapidly, once developed and approved. 
(29) The EU will undertake studies to establish a priority list of “pull 
incentives” to engage private industry in the research and development of 
new tools and interventions, based on a cost-benefit analysis and on their 
feasibility. The studies should, in particular, analyse advanced markets 
mechanisms, cash premiums, an international financing facility for vaccines, 
and transferable privileges – such as IPR extensions or fast-track approvals. 
(30) The EC will support a selected number of public-private partnerships 
(PPPs), and global initiatives. The aim will be to establish the coordination 
and synergy that are necessary and the appropriate level of resources required 
to accelerate R&D efforts, to estimate the health, social and economic 
benefits that could be derived from the development and use of new 
diagnostic, preventive and therapeutic technologies, and to prepare 
communities for the introduction of HIV/AIDS vaccines and microbicides. 
The EC will enhance cooperation within Europe to ensure the viability and 
progress of innovative research initiatives towards the development of 
priority products. 
3.5. Strengthened partnerships 
The EC will consult and involve a wide group of partners in ongoing dialogue 
through the EC Stakeholder Forum and regional consultations. The Stakeholder 
Forum will invite representatives of civil society, including people directly affected 
by the three diseases to enhance their role and voice in the policy dialogue at global 
level. The involvement of the private sector, including industry (e.g. Private 
Investors for Africa) and private foundations, remains crucial. 
The EC will collaborate with and further support key organisations and global 
initiatives through effective global partnerships sharing efforts, risks and benefits to 
translate a common vision into a common voice and common action. The EC will 
assess the relative merits of working in global partnerships by assessing what the 
partnership offers in terms of: 
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• unique expertise, wide presence in countries, key resources that make it a 
particularly useful partner to make EU action more effective and efficient; 
• whether the benefits for the EU outweigh the input in terms of resources, staff 
and time; and 
• whether the EC as an organisation offers the partner specific comparative 
advantages and what the position of EU MSs is towards the potential partner. 
In addition to the stakeholders mentioned under 3.4, and based on an assessment of 
these three criteria, the EC proposes to work with the following partners at global 
level. WHO (under the EC-WHO strategic partnership) and UNAIDS – are key 
partners for the EC. These organisations offer both technical expertise, e.g. on 
pharmaceutical policy, regulatory issues and health monitoring, and disease-specific 
expertise through RBM and Stop TB. The EC will also cooperate closely with 
UNFPA to ensure that synergies are explored between initiatives in this field and 
those focusing on the Cairo agenda, with ILO, under the EC-ILO strategic 
partnership, and with UNICEF on mother-and-child health and education issues. 
3.6. A strong European voice 
The EC has a strong role and responsibility, together with the EU MSs, in terms of 
establishing, representing and defending the European vision and commitments 
internationally. Political dialogue with countries is crucial to addressing and 
defending basic principles and to raising and discussing sensitive issues at the 
highest political level. 
At global level, the EC voice may be due to a formal mandate, e.g. in trade policy, or 
to the EC taking the initiative or being asked by EU MSs to take on such a role. This 
is sometimes also the case in UN processes, where it is the EU MSs that are fully 
represented and have a formal voice. Examples include preparations of UNGASS, 
follow-up to the MDGs, and UN conferences on gender equality and SRHR – all of 
which are intimately linked to the policy issues discussed in this PfA. The EC can 
play a constructive role both by projecting and defending an EU position 
internationally and by offering non-EU members a credible partner for dialogue. 
Close cooperation between the EC and EU MSs remains crucial in the UN as well as 
in the G8 context. The EC also needs to be able to co-fund international conferences 
and seminars where progress is assessed and new policy and practice discussed. 
4. NEXT STEPS 
Programming decisions and budget allocations with respect to actions proposed in 
this PfA will be made in accordance with the structure of instruments determined for 
the next financial perspectives. 
EU MSs are invited to work closer together with the EC in taking specific actions 
forward at country level, e.g. sharing expertise, reflecting the EU common vision in 
policy dialogue, mapping and planning technical assistance for capacity building, 
and formulating joint measures to support countries in addressing human resource 
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constraints. The EC will take the decisions required to promote synergy and provide 
a coherent response to the three diseases across relevant policy areas. 
The EC will monitor and report on the implementation through annual and mid-
term reviews of country specific instruments, FP7, and monitoring and evaluation 
mechanisms of the Global Fund. The EC will work towards agreement with partners 
in countries on the use of one monitoring and evaluation framework with common 
indicators. In 2008 and 2010, the Commission will present comprehensive progress 
reports to Parliament and the Council on the implementation, outputs and impact of 
the PfA. 
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Annex 1 – Principles for country strategies to confront the three diseases 
Civil society, in particular people infected and affected by the diseases, together with 
representatives of the social partners and the private sector should be active partners 
in policy dialogue, priority setting, and the design, implementation and monitoring of 
strategies. 
Strategies should be evidence-based and represent an appropriate policy-mix, 
including information, prevention (e.g. condoms and LL-ITNs), harm reduction (e.g. 
needle exchange for injecting drug users), vector control measures against malaria 
(e.g. environmental and sanitation measures and intra-door residual spraying with 
DDT), treatment and care, and impact alleviation. Information and prevention remain 
crucial components of any strategy aiming to halt the spread of HIV/AIDS, malaria 
and TB. These strategies should also help to increase human security and the 
protection of human rights – including women’s rights and the rights of the child. 
They should also help to overcome stigma and discrimination among those infected 
and affected, including groups at higher risk of HIV/AIDS infection e.g. commercial 
sex workers, men having sex with men, injecting drug users and prisoners, and 
protect the rights of such people while at the same time providing access to essential 
services based on equity. 
The translation of policies into strategies requires sufficient and predictable financing 
based on solid costing and gap analyses, adequate allocation of domestic resources 
according to capacities and topping-up by external aid to support the strategy. 
Strategies should be cross-sectoral and be both an integrated part of, and reflected in 
comprehensive actions for developing health and other social services to improve 
health outcomes. Synergies should be explored with strategies to promote SRHR and 
gender equality. All sectors should consider the impact of the three diseases and how 
their sector can contribute through an appropriate response. 
Inclusion of strategies into MDG-based poverty reduction programmes should be 
promoted in developing countries. 
Gender equality should be promoted through these strategies, and reflect the fact that 
girls and women carry a heavier burden and are affected more often and at an earlier 
age by HIV/AIDS than men. HIV/AIDS strategies must be designed to address the 
constraints that make it difficult for girls to use prevention tools, treatment and care 
services. The role and responsibilities of men in HIV/AIDS prevention should also 
be highlighted, including in terms of norms and responsible sexual behaviour. 
Strategies should reflect the fact that family-based and community-based care often 
plays a crucial role in alleviating the burden of the disease, including as an 
alternative to institutional care for orphans and vulnerable children. The age 
dimension also needs to be taken into account, with a particular focus on children 
affected by malaria, orphans and vulnerable children affected by HIV/AIDS and 
elderly people who have higher rates of TB infection (often undiagnosed) and who 
are also often left to take care of such children and may need support to this end in 
terms of social protection or allowances. Inheritance and social rights for widows and 
orphans need to be protected through legislation and put into effective practice. 
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Strategies should address other specific vulnerable groups, e.g. workers in unhealthy 
environments, refugees, migrants, internally displaced people, minority communities, 
and people with disabilities, who are often placed in vulnerable situations. 
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Annex 2 – Indicative monitoring framework for actions 2007-2011 
 ACTION/ 
INITIATIVE 
PARTNERS MONITORING AND OUTCOMES 
 COUNTRY ACTION   
1. Political dialogue EC 
EU MSs 
- Political dialogue on key issues relating to leadership, governance, human rights, vulnerable groups, 
and stigma and discrimination. 
2. Develop a toolkit for policy 
dialogue, programming and 
monitoring for EC/EU 
delegations; and for awareness 




WHO (+UNAIDS, RBM, 
StopTB) 
- Toolkit prepared and distributed to Delegations. 
- Training at HQs organised. 
- HIV/AIDS, malaria and TB, including the critical issues, raised in the dialogue in more countries; 
reports by social sector experts. 
- HIV/Malaria/TB analysis, where relevant, included in CSP programming and review exercises. 
3. Sharing health expertise between 
EU MSs 
EC Delegations, EU MSs - Mapping of EC/EU health experts. 
- Arrangements for joint working or sharing of EU health expertise. 
- EU health experts present in policy and political dialogue in PRSP, health sector, and disease-specific 
reviews, as reported annually by EC Delegations. 
- Shared situation analysis, programming, monitoring and reporting increasingly used. 
- Development of a joint framework for analysis and reporting. 
 
4. Social responsibility for EC staff 
and their families 
EU MSs 
ILO 
- Education and prevention programmes in EC delegations. 
- Adequate social protection schemes for EC Delegations and RELEX services, which support staff and 
their families affected by the diseases, in line with good practice developed by EU Member State 
development agencies. 




WHO (+UNAIDS, RBM, 
StopTB) 
- Plan for shared TA and code of conduct agreed in countries with high presence of EU donors, based 
on mapping of resource persons. 




PARTNERS MONITORING AND OUTCOMES 
6. Supporting national human 
resources for health policy and 
strategies which build HR 
capacity 
EC Delegations (in particular 
in countries with EC sector 
or macroeconomic budget 
support) 
EU MSs and their health 
professions councils 
Dialogue with IMF, AU, 
NEPAD 
- Incentives and strategies developed and supported by the EU to retain health providers and to 
strengthen research capacities through training of professionals and the creation of more attractive 
career conditions and perspectives. 
- Bretton Woods institutions acknowledging the exceptional situation in terms of human resources in 
the health sector and contributing to an enabling environment to address this. 





- Capacity increased for research (social, clinical, operational), including training of human resources, 
in several African countries with heavy burden for the three diseases and accompanied by adequate 
institutional capacity strengthening. 
- Support by EC, EU MSs, EDCTP and other global stakeholders for further scientific and technical 
cooperation between health care and health research, complementing EC supported clinical trials 
activities. 
8. Building capacity for 
pharmaceutical policy 
WHO (+UNAIDS, RBM, 
StopTB) 
- Support provided through WHO, including on the following key issues on pharmaceutical policy: , 
including Multi-Drug Resistant TB; substitution therapy for injecting drug users; affordable, rational 
and supervised use of relevant malaria treatment, including Artemisinin-based combination therapy; 
provision of second-line treatment for HIV/AIDS; treatment guidelines for women of reproductive age 
and children; and guidance on drug quality. 
- Improved and more rational use of pharmaceutical products in developing countries. 
9. Building capacity for 
procurement of pharmaceutical 
products and commodities 
WHO (+UNAIDS, RBM, 
StopTB) 
 
- Prices on pharmaceutical products and SRH commodities published. 
- Lowest prices paid by least developed countries by end of 2011, as seen from prices published. 
10. Increase synergy between 
programmes and services on the 
three diseases and for children’s 




- Child health programmes and SRH services increasingly providing information and preventive 
commodities for the three diseases. 
11. Making schools safe for children 
and including prevention of the 
three diseases in curricula 
International organisations, 
e.g. UNICEF and UNFPA, 
and teachers and parent 
organisations 
- School safety raised in policy and political dialogue, reports by EC delegations with education as 
focal sector, taking into account the work done by e.g. UNICEF and UNFPA on rights-based, child-
friendly schools and involve children, parents and teachers in their design and implementation. 
- Codes of conduct established and respected by teachers. 




PARTNERS MONITORING AND OUTCOMES 
12. Assessing the impact of the three 
diseases on human security and 
stability at state level 
EC - Study on human security and stability. 
- EU response proposed for critical countries. 
13. Mainstreaming efforts to 
confront the three diseases in 
emergency operations 
EC - ECHO guidelines for HIV/AIDS and malaria finalised. 
- Training and tools provided for humanitarian workers. 
- The three diseases addressed in the situation of CSPs subject to LRRD. 
14. Training of peacekeeping forces 




-Accompanying measures of EC support for the AU Peace facility. 
15. Collecting of relevant data for 
annual monitoring of progress 
indicators13 
EU MSs 
WHO (+UNAIDS, RBM, 
StopTB) 
Health Metrics Network 
 
- Sex- and age-disaggregated data collected and analysed to monitor meaningful indicators on the three 
diseases. 
- Capacity of national monitoring and reporting systems strengthened, including to monitor essential 
services. 
16. Financial resources to confront 




- Adequate and predictable funding of the Global Fund, including a significant EU contribution. 
17. Highly cost-effective 






- EC support and funding provided for these interventions through relevant organisations in partnership 
with heavy-burden countries. 





- MDG rating analysis for PRSPs developed. 
- PRSPs increasingly focused on achieving the MDGs with increased resources allocated to MDG6. 
                                                 
13 Examples include: Voluntary Counselling and Testing (VCT) coverage, Prevention of Mother-To-Child Transmission (PMTCT) coverage, and Highly Active Anti-
Retroviral Therapy (HAART) coverage (for HIV/AIDS); use of LL-ITNs for under-fives and pregnant women, and Intermittent Preventive Treatment (IPT) during 
pregnancy and possibly childhood (for malaria); and DOTS detection and cure rate (for TB). 





PARTNERS MONITORING AND OUTCOMES 
 GLOBAL ACTION   
19. Strengthening regional 
cooperation to confront the three 
diseases in Southern Africa and 
South-East Asia, expanding to 
other regions 
EC - EC regional health advisors appointed. 
- Annual regional reports on country actions. 
- Regional cooperation established on key issues and examples of good practice shared. 
20. Monitoring and promoting of the 
anti-trade diversion Regulation 
EC 
Dialogue with industry 
- Monitoring reports published with meaningful and transparent price data. 
21. Promoting price transparency WHO (including RBM and 
StopTB) and UNAIDS 
MSF 
GLOBAL FUND 
(see action point 9) 
- Prices of pharmaceutical products and commodities purchased through EC support published. 
22. Implementing the August 2003 
decision of the WTO 
EC 
EU MSs, 
Dialogue with WTO 
- EC legislation to implement the August Decision adopted by Council and Parliament. 
- August Decision fully incorporated into the TRIPs Agreement through a formal amendment. 
- Biannual report of implementation of the August agreement in third countries. 
23. Developing scientific and 
regulatory capacity of partner 
countries 
EC 
WHO, EMEA, EU MSs 
Regulatory bodies 
 
- Use of Article 58 of Regulation (EC) No 726/2004 for the evaluation of medicines for developing 
countries. 
- Specific guidelines developed on key products, e.g. microbicides and vaccines – consistent with the 
risk-benefit profile of products in the country context, and age and gender aspects when assessing 
safety and efficacy. Support will be given through TA, training and exchange schemes. 
- Training on regulatory capacity provided by experts under EC Framework contract and/or WHO. 
- International conference organised by EMEA and WHO focusing on regulatory issues relating to 
microbicides. 
24. Establishing regional schemes of 
mutual recognition for marketing 
authorisation 
Setting up an international 





- Regional capacity developed in terms of centres of regulatory expertise. 
- Regional scheme of mutual recognition for marketing authorisation established. 
- Needs and opportunities for setting up an international advisory committee fully explored. 




PARTNERS MONITORING AND OUTCOMES 





- Continued and expanded EC funding for the WHO prequalification project. 
- Annual report on prequalification progress in relation to production map in developing countries. 
26. Innovative responses to the 
human resource crisis among 
health providers 
EU MSs, 
AU, NEPAD, HL Forum on 
the Health MDGs 
- EC support for AU-NEPAD in tackling the human resource crisis, ultimately leading to increased 
training, improved working conditions and better availability of health providers in Africa. 
27. Preparing new EC policy on a 
European response to the human 
resource crisis among health 
providers 
EC - EC Communication on “HR-diversion” adopted and ways forward explored with EU MSs. 
28. Supporting research and 
development of priority tools and 
interventions, including clinical 




- EC funding leading to results in terms of new tools and interventions (e.g. EDCTP). 
- Research collaboration with and participation of disease-endemic countries further strengthened, 
through excellence centres in disease-endemic countries. 
- Key areas of research (basic, preclinical and clinical) funded under FP7 and results effectively used in 
EC policy development and implementation in the fight against the three diseases. 
29. Evaluating the effectiveness and 
potential cost of implementing 
pull incentives within EC 
competence 
EC - Studies finalised and EC policy proposal in terms of new incentives presented. 
30. Support for priority tools 
through public-private 




PPPs and global initiatives 
 
- EC and EU support for PPPs and global initiatives working on priority tools and interventions, e.g. 
HIV/AIDS vaccines and microbicides. 
 
